Rein Therapeutics Inc (RNTX) Stock Forecast & Price Target
Rein Therapeutics Inc · NASDAQ
$0.83-0.03 (-3.82%)
15-min delayed · Sep 9, 3:45 PM ET · Get real-time quotes →
The Quantellect read.Of the 3 firms covering Rein Therapeutics Inc, 2 rate it Buy or better, 1 sit at Hold, and 0 rate it Sell or worse, a moderate buy consensus. Targets range widely, $4.00 to $8.00 (about 2.0x), a sign of real disagreement on valuation. The average target of $6.00 sits 623% above the current $0.83. The rating mix has stayed broadly stable, with Buy-side ratings edging up from 1 to 2 over recent months. On the fundamentals, the Street sees consensus EPS building from about $-0.13 next quarter toward $-0.47 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS3 ratings
Moderate Buy
Strong Buy00%
Buy267%
Hold133%
Sell00%
Strong Sell00%
Based on 3 analysts giving stock ratings to Rein Therapeutics Inc.
As of Sep, 2 of 3 firms rate RNTX a Buy (1 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
RNTX EPS & revenue forecast
EPS · NEXT QUARTER
$-0.13
Range $-0.15 – $-0.10 · 2 analysts · -90% YoY
Next period, 2 analysts expect Rein Therapeutics Inc to earn $-0.13 a share (range $-0.15 – $-0.10), versus $-1.22 a year earlier. Full-year consensus is $-0.46, growing to $-0.47 the year after.
REVENUE · NEXT QUARTER
$0
Range $0 – $0 · 2 analysts
Revenue is expected to reach $0 (range $0 – $0). Full-year consensus is $0, rising to $0 next year.
Top analysts covering Rein Therapeutics Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on RNTX.
#1
BF
Brandon Folkes
HC Wainwright & Co. · Rank #221
Buy
$8.00+863.9% to target
Overall win rate
42%
+ Follow
#2
Jason McCarthy
Maxim Group · Rank #428
Buy
$4.00+381.9% to target
Overall win rate
32%
+ Follow
#3
KD
Kemp Dolliver
Brookline Capital
Hold
No targeton RNTX
Coverage
—
+ Follow
#4
KD
Kemp Dolliver
Brookline Capital Markets
Hold
No targeton RNTX
Coverage
—
+ Follow
RNTX stock forecast FAQ
What is RNTX's average 12-month price target?+
The 2 analysts with a live target average $6.00 for Rein Therapeutics Inc over the next 12 months, ranging from a $8.00 high to a $4.00 low.
Is RNTX stock a Buy, Sell or Hold right now?+
The current consensus is Moderate Buy. Of the 3 analyst ratings, 2 are Buy or Strong Buy, 1 are Hold, and 0 are Sell or Strong Sell.
What are the highest and lowest price targets for RNTX?+
The Street-high target is $8.00 (HC Wainwright & Co.), and the Street-low is $4.00 (Maxim Group). The average of all 2 active targets is $6.00.
How many Wall Street analysts cover RNTX?+
3 analysts have an active rating on Rein Therapeutics Inc, and 2 firms carry a live 12-month price target.
Who is the most accurate analyst covering RNTX?+
Among analysts who currently cover RNTX, Brandon Folkes of HC Wainwright & Co. has the strongest overall Quantellect track record (Rank #221). Their current call is Buy with a $8.00 target.
What is Rein Therapeutics Inc's projected EPS for next quarter?+
The consensus estimate is $-0.13 per share (range $-0.15 – $-0.10) across 2 analysts. Full-year EPS is projected at $-0.46, rising to $-0.47 the following year.
How much revenue is Rein Therapeutics Inc expected to report next quarter?+
Consensus revenue is $0 (range $0 – $0). Full-year revenue is projected at $0, growing to $0 next year.
Have analysts been upgrading or downgrading RNTX lately?+
As of Sep, 2 of 3 firms rate RNTX a Buy (1 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their RNTX calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.
